EntreMed Panzem To Boost Bioavailability Under Elan Supply Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Elan will reformulate and manufacture Panzem (2-methoxyestradiol) as an oral liquid formulation using its NanoCrystal technology. EntreMed expects to initiate a clinical oncology program in 2005 using the new formulation.
You may also be interested in...
EntreMed Hopes To Partner, Rapidly Advance Promising Kinase Inhibitor
With no revenue for first half of 2008, finding a partner is crucial to development of EMND-2076.
EntreMed Hopes To Partner, Rapidly Advance Promising Kinase Inhibitor
With no revenue for first half of 2008, finding a partner is crucial to development of EMND-2076.
Cymbalta Once-Daily Dosing Not Vital To Product's Success, Lilly Suggests
Lilly says it has data on twice-daily Cymbalta dosing, and analysts express concern that the company has not previously discussed the possibility of b.i.d. administration in labeling. Exec VP-Science & Technology Paul maintains Cymbalta is also "very effective and very safe" taken once a day.